Kiebik A, Szlasa W, Novickij V, et al
Several GLS inhibitors have been developed, among which CB-839 is currently undergoing clinical trials as a potent, orally bioavailable GLS-selective inhibitor for the treatment of various cancers, including TNBC, NSCLC, and colon cancer (NCT03057600, NCT03057600, NCT03057600, NCT03057600, NCT03057600, NCT03057600)
Issues related to agglomeration, long-term stability, regeneration efficiency, scalability, cost-effectiveness, and potential toxicity require continued research efforts through surface modification strategies, functionalization techniques, and composite material development
a relative increase in ferric ions may contribute to the pathological process in the substantia nigra 11
The Bigger Picture This advisory committee meeting is part of a broader and ongoing effort by FDA to impose order on the compounding landscape, particularly with respect to peptides and biologics that have grown popular in wellness, sports medicine, longevity, and integrative health settings